Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chengdu Olymvax Biopharmaceuticals Inc operating margin has been in a 5-year decline. The average rate of decline per year is -16.2%.
The historical rank and industry rank for Chengdu Olymvax Biopharmaceuticals's Operating Margin % or its related term are showing as below:
SHSE:688319'
s Operating Margin % Range Over the Past 10 Years
Min: -34698.76 Med: 8.3 Max: 100
Current: 14.1
SHSE:688319's Operating Margin % is ranked better than 83.94% of 940
companies
in the Biotechnology industry
Industry Median: -86.19
vs SHSE:688319: 14.10
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Chengdu Olymvax Biopharmaceuticals Operating Margin % Related Terms
Chengdu Olymvax Biopharmaceuticals Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688319 vs VRTX, REGN, ALNY: Operating Margin % Comparison
For the Biotechnology subindustry, Chengdu Olymvax Biopharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Olymvax Biopharmaceuticals Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Olymvax Biopharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Chengdu Olymvax Biopharmaceuticals's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Olymvax Biopharmaceuticals (SHSE:688319) has a Operating Margin % of 18.73% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. This is 126% above median its historical median of 8.30. According to the industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #151 out of 940 companies in the Biotechnology industry, placing it in the top 16.1%.
Is Chengdu Olymvax Biopharmaceuticals' Operating Margin % too high?
Chengdu Olymvax Biopharmaceuticals' current Operating Margin % of 18.73% is 126% above median its 10-year median of 8.30. Based on the distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #151 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Chengdu Olymvax Biopharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Olymvax Biopharmaceuticals' Operating Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Olymvax Biopharmaceuticals ranks #151 out of 940 companies for Operating Margin %. This places Chengdu Olymvax Biopharmaceuticals in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Chengdu Olymvax Biopharmaceuticals and its competitors. Chengdu Olymvax Biopharmaceuticals's current Operating Margin % is 18.73%, which is 126% above median its own 10-year median of 8.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Olymvax Biopharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals (SHSE:688319) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥23.13, compared to a current price of ¥27.01 — trading 16.8% above its estimated fair value. The current Operating Margin % is 18.73%, which is 126% above median its 10-year median of 8.30. Chengdu Olymvax Biopharmaceuticals' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Chengdu Olymvax Biopharmaceuticals (SHSE:688319), the current Operating Margin % is 18.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Olymvax Biopharmaceuticals stock appears to be overvalued.
The current stock price of ¥27.01 is trading 16.8% above its estimated GF Value™ of ¥23.13.
GuruFocus considers Chengdu Olymvax Biopharmaceuticals to be Modestly Overvalued.
Key valuation signals for SHSE:688319:
Operating Margin %: 18.73% (126% above median its 10-year median of 8.30)
GF Value™: ¥23.13 vs. price of ¥27.01 (16.8% above fair value)
No single metric tells the full story. See the SHSE:688319 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Olymvax Biopharmaceuticals Business Description
Chengdu Olymvax Biopharmaceuticals Inc is engaged in the research and development, production, and sales of human vaccines, focusing on innovative products.
73GF Score
Get the complete analysis for SHSE:688319
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688319 has been successfully added to your 
